Key clinical point: Combining the TLR9 agonist CMP-001 with pembrolizumab produced responses in melanoma patients who had progressed on prior anti–PD-1 therapy.
Major finding: The overall response rate was 25% among patients who received the optimal formulation of CMP-001, and the median duration of response has not been reached at a median follow-up of 16.9 months.
Study details: Phase 1 study of 144 patients who received the combination.
Disclosures: The study is sponsored by Checkmate Pharmaceuticals. Dr. Kirkwood disclosed relationships with Amgen, BMS, Immunocore, Iovance, Novartis, Elsevier, Castle, Merck, and Checkmate.
Kirkwood J et al. SITC 2019, Abstract O85.